Home > Oncology > Liquid biopsies helpful in prostate cancer, but most not ready for routine use

Liquid biopsies helpful in prostate cancer, but most not ready for routine use


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
European Urology
Reuters Health - 29/01/2021 - Liquid biopsies have the potential to guide therapeutic decision making in prostate cancer, but issues such as assay standardization, cost and accessibility need to be addressed before they can be implemented in routine practice, researchers say. "There are many different technologies to interrogate tumor features from liquid biopsies," Dr. Joaquin Mateo of Vall d'Hebron University Hospital in Barcelona told Reuters Health by email. "Some of them have already been validated and received regulatory clearance, such as CTC counts, but many are in development." "It is critical that we integrate these technologies into clinical trials so we can accelerate their development," he said. "Hence, there is a need for all stakeholders - academic institutions, pharmaceutical and biotech companies - to push together for validating and clinically qualifying these novel biomarkers, so we can use them properly to improve patient care." "Clinician...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on